معرفی
Yulia Maxuitenko is an Associate Research Professor in the Department of Drug Discovery and Development at Auburn University's Harrison College of Pharmacy, where she has served since 2021. She holds a Ph.D. in Pharmacology and Toxicology from Dartmouth College and a B.S./M.S. in Environmental Sciences from Moscow Institute of Chemical Technology. Her office is located at 347 Pharmacy Research Building, Auburn, AL.
Her research focuses on oncology drug discovery, with emphasis on RAS/PDE10 inhibitors, cancer chemoprevention, and immunotherapy enhancement. She leverages in vivo pharmacology models and has contributed to preclinical development of four FDA-approved drugs. Key interests include targeting nucleotide cycling in RAS-driven cancers and blocking Wnt/β-catenin signaling via PDE inhibition to suppress tumorigenesis.
Publications (2020-2021) predominantly explore molecular mechanisms of RAS/PDE10 inhibition, combination immunotherapies, and transporter-targeted chemosensitization, with applications in lung, colon, breast, and pancreatic cancers. Trends highlight translational drug development from biochemical pathways to preclinical validation.
Active Grants:
- NIH/NCI R01CA254197-01 (2021-26): Novel RAS inhibitor for lung cancer (Co-I)
- NIH/NCI R01CA238514-01 (2020-25): Sulindac derivatives for cancer immunotherapy (Co-I)
- NIH/NCI R01CA197147-04 (2016-23): PDE10A targeting in lung cancer chemoprevention (Co-I)
- Breast Cancer Research Foundation Alabama (2021-22): β-catenin blockers for breast cancer (Co-I)
She previously managed the Chemotherapy and Chemoprevention Group at Southern Research Institute and collaborates with Drs. Piazza, Keeton, and Chen at Auburn on RAS/PDE10 therapeutics.
